Synspira Therapeutics Adds Drucy Borowitz, MD, to Board of Directors Posted on October 28, 2020 by Kathryn Kilroy Continue reading “Synspira Therapeutics Adds Drucy Borowitz, MD, to Board of Directors”
Synspira Therapeutics Presents Data at 34rd Annual North American Cystic Fibrosis Conference on Effect of SNSP113 on Recalcitrant Methicillin Resistant Staphylococcus aureus (MRSA) Posted on October 23, 2020October 23, 2020 by Kathryn Kilroy Continue reading “Synspira Therapeutics Presents Data at 34rd Annual North American Cystic Fibrosis Conference on Effect of SNSP113 on Recalcitrant Methicillin Resistant Staphylococcus aureus (MRSA)”
Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis Posted on October 20, 2020October 20, 2020 by Kathryn Kilroy Continue reading “Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis”
Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement to Develop Broad-spectrum Enzyme Replacement for Malabsorption Syndromes Posted on February 12, 2020February 12, 2020 by Steve Polito Continue reading “Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement to Develop Broad-spectrum Enzyme Replacement for Malabsorption Syndromes”
Synspira Therapeutics Presents Data on Effect of SNSP113 on Chronic, Recalcitrant Nontuberculosis Mycobacteria (NTM) Pulmonary Infections at 33rd Annual North American Cystic Fibrosis Society Conference Posted on October 31, 2019October 31, 2019 by Kathryn Kilroy Continue reading “Synspira Therapeutics Presents Data on Effect of SNSP113 on Chronic, Recalcitrant Nontuberculosis Mycobacteria (NTM) Pulmonary Infections at 33rd Annual North American Cystic Fibrosis Society Conference”
Synspira Therapeutics Appoints Industry Leaders Dr. Alexey Margolin And Robert K. Coughlin To Board Of Directors Posted on October 28, 2019October 28, 2019 by Kathryn Kilroy Continue reading “Synspira Therapeutics Appoints Industry Leaders Dr. Alexey Margolin And Robert K. Coughlin To Board Of Directors”
Synspira Therapeutics Presents Data at 42nd Annual European Cystic Fibrosis Society Conference on Effect of SNSP113 on nontuberculosis Mycobacteria and Burkholderia Pulmonary Infections Posted on June 7, 2019June 7, 2019 by Kathryn Kilroy Continue reading “Synspira Therapeutics Presents Data at 42nd Annual European Cystic Fibrosis Society Conference on Effect of SNSP113 on nontuberculosis Mycobacteria and Burkholderia Pulmonary Infections”
Synspira Therapeutics SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease Posted on April 23, 2019October 28, 2019 by Kathryn Kilroy Continue reading “Synspira Therapeutics SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease”
Synspira Therapeutics Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union Posted on April 10, 2019February 11, 2020 by Kathryn Kilroy Continue reading “Synspira Therapeutics Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union”
Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer Posted on March 27, 2019March 27, 2019 by Steve Polito Continue reading “Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer”
Toggle navigation
Toggle navigation